Professional Marketing briefs

Novartis announced a reorganization of its US business into units focusing on primary care, MS, respiratory disease and neuroscience, along with a 20% reduction in its US headquarters staff. With Diovan going off-patent in 2012, it no longer makes sense for the company to focus its sales force on primary care physicians, CEO Joe Jimenez (left) said. He told The Wall Street Journal that the company would beef up its sales force in China using its own employees, bucking the trend towards outsourcing sales and research staff in China.  

Avanir Pharmaceuticals named Michael McFadden VP US sales and managed markets. McFadden, who joins from Amylin, will be responsible for staffing, training and managing the planned Zenvia specialty sales force. Avanir hopes to launch Zenvia for pseudobulbar affect, a neurological disease which causes uncontrollable laughing or crying, next year.

Specialty and hospital sales forces are no longer contracting, according to a Cutting Edge Information survey which found a leveling off of headcount and budget over the past two years. Daily calls by specialty and hospital reps was steady, said CEI, and per-rep visits for pharmas were up.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.